Smartphone-delivered CBT improves glycemic control in people with type 2 diabetes - medwireNews

1 year ago 38

medwireNews: Findings from a randomized controlled proceedings published successful Diabetes Care suggest that for radical with benignant 2 diabetes, the transportation of cognitive behavioral therapy (CBT) via a integer therapeutic app, connected apical of modular of care, whitethorn trim glycated hemoglobin (HbA1c).

The survey included 669 adults (58% White, 28% Black, 16% Latino) aged an mean of 58 years with benignant 2 diabetes and glycated hemoglobin (HbA1c) levels of 7.0 to little than 11.0% (53 to <97 mmol/mol) who were randomly assigned to person entree to a integer therapeutic app delivering CBT (BT-001) oregon a power app, some connected apical of modular care.

The researchers observed that radical successful the BT-001 radical had importantly little HbA1c than those successful the power radical aft 90 days of utilizing the app. In the BT-001 arm, HbA1c decreased by 0.28% from 8.2% (66 mmol/mol) astatine baseline, compared with an summation of 0.11% from 8.1% (65 mmol/mol) successful the power group. This resulted successful a between-group quality of 0.39% astatine time 90.

“The magnitude of HbA1c simplification successful the BT-001 radical accrued successful parallel with vulnerability to the therapy, arsenic indicated by the fig of modules completed,” constitute Judith Hsia (CPC Clinical Research, Aurora, Colorado, USA) and co-authors. They accidental that this “supports the value of engagement, accordant with in-person CBT and behavioral interventions successful general.”

There were nary adverse events attributed to the app usage and nary adverse instrumentality effects were observed.

“Delivery of a cognitive behavioral involution via smartphone app tin supply a scalable enactment for improving glycemic control,” concludes the team.

medwireNews is an autarkic aesculapian quality work provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, portion of the Springer Nature Group

Diabetes Care 2022; doi:10.2337/dc22-1099

Read Entire Article